alarm-ringing ambulance angle2 archive arrow-down arrow-left arrow-right arrow-up at-sign baby baby2 bag binoculars book-open book2 bookmark2 bubble calendar-check calendar-empty camera2 cart chart-growth check chevron-down chevron-left chevron-right chevron-up circle-minus circle city clapboard-play clipboard-empty clipboard-text clock clock2 cloud-download cloud-windy cloud clubs cog cross crown cube youtube diamond4 diamonds drop-crossed drop2 earth ellipsis envelope-open envelope exclamation eye-dropper eye facebook file-empty fire flag2 flare foursquare gift glasses google graph hammer-wrench heart-pulse heart home instagram joystick lamp layers lifebuoy link linkedin list lock magic-wand map-marker map medal-empty menu microscope minus moon mustache-glasses paper-plane paperclip papers pen pencil pie-chart pinterest plus-circle plus power pushpin question rain reading receipt recycle reminder sad shield-check smartphone smile soccer spades speed-medium spotlights star-empty star-half star store sun-glasses sun tag telephone thumbs-down thumbs-up tree tumblr twitter user users wheelchair write yelp youtube

VA Reinstates Bevacizumab As Off-Label Treatment For AMD.


Medscape¬†Share to FacebookShare to Twitter (11/9, Waknine) reports, “The US Department of Veterans Affairs (VA) has announced the reinstatement of bevacizumab (Avastin, Genentech unit of Roche AG) as an option for the off-label treatment of wet age-related macular degeneration (AMD).” Going forward, “the VA will now allow one patient dose per manufacturer’s vial of bevacizumab, with the caveat that patients be carefully screened before receiving treatment and be fully informed of the health risks associated with off-label therapy.” Medscape points out that even though “ranibizumab (Lucentis) is specifically approved to treat AMD, bevacizumab has a similar method of action and has been employed by the VA to cut costs (at $50 vs. $2,000 per dose), despite concerns regarding the compounding of intravitreal injections from an intravenous product.”¬†